Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

AdComNegative

AI Analysis

Summary

The FDA raised concerns about the efficacy of Capricor Therapeutics' Duchenne treatment ahead of a scheduled hearing, adding uncertainty to the drug's regulatory pathway.

Outcome Details

FDA raised questions about efficacy ahead of hearing

Importance:6/10

Sentiment:

-0.60

FDADuchennerare diseaseregulatory setbackAdCom hearing

Related Companies

$TWST

Read the original article

Published by STAT News on July 27, 2026 1:08 PM

Read Original